is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Good news! We’ve extended the CPhI Japan Connect platform, keeping it open until 31st May 2021 to give you more time to connect and do business in Japan. Register (first-time visitors) or Log in (previous visitors) now to connect with event exhibitors, schedule video meetings, source innovative products, and plan future collaboration.
Register or Log in Now to:
This report highlights trends in Japan’s pharma market, notably how costly, long-listed products will be replaced due to generic and biosimilar industries continuing to grow in volume and market share. It also discusses increased internationalisation of innovation, with a rise in acquisitions and partnerships with academia.
Our 2021 Pharma Outlook report has been published in collaboration with some of Pharma’s biggest names to provide key insights that will help you navigate the next 12 months and grow your business.
2020 has been one of the most turbulent years in recent history, casting a shroud of uncertainty over the pharma industry’s future.
Pharma’s response to the COVID-19 pandemic, in terms of vaccine development and treatment distribution, has grabbed many recent headlines, but the major challenges facing the pharma industry are by no means exclusively Coronavirus related.
In interviews with some of the industry’s experts, the 2021 Pharma Outlook report identifies major and emerging trends that will be prominent in 2021.